Table 2.
ORR, DCR and OS rate in different subgroups.
| Source a | Outcome | Heterogeneity | Rate (95% CI) % |
|---|---|---|---|
| 13-15,22,24-26 | ICI ORR | Fixed | 18.3 (15.8-20.9) |
| 13,24,26 | Pembrolizumab ORR | Fixed | 16.3 (12.3-20.2) |
| 14,26 | Camrelizumab ORR | Random | 24.2 (12.4-36.0) |
| 15,22 | Nivolumab ORR | Fixed | 18.5 (13.9-23.1) |
| 14,15,22,25,26 | ICI DCR | Random | 38.4 (30.1-46.8) |
| 26 | Pembrolizumab DCR | —— | 28.0 (35.2-43.2) |
| 14,26 | Camrelizumab DCR | Fixed | 46.1 (40.0-52.2) |
| 15,22 | Nivolumab DCR | Random | 33.0 (23.4-42.6) |
| 14,24,26 | ICI 6-month OS rate | Random | 57.1 (46.6-67.7) |
| 24,26 | Pembrolizumab 6-month OS rate | Fixed | 50.8 (42.7-59.0) |
| 14 | Camrelizumab 6-month OS rate | —— | 63.0 (56.7-69.3) |
| 13-15,24,26 | ICI 12-month OS rate | Random | 37.5 (30.6-44.4) |
| 13,24,26 | Pembrolizumab 12-month OS rate | Random | 34.9 (26.0-43.7) |
| 14 | Camrelizumab 12-month OS rate | —— | 34.0 (27.0-40.1) |
| 15 | Nivolumab 12-month OS rate | —— | 47.0 (40.2-53.8) |
| 13,24,25 | PD-L1+ ORR | Random | 22.2 (10.5-34.0) |
| 13,24,25 | PD-L1+ DCR | Random | 48.0 (34.2-61.9) |
| 24,25 | PD-L1- ORR | Fixed | 6.7 (0.9-12.4) |
| 24,25 | PD-L1- DCR | Fixed | 26.9 (12.0-41.7) |
a
Source appertain to corresponding references; ORR, objective response rate; DCR, disease control rate; OS, overall survival; ICI, immune checkpoint inhibitor.